英国生命科学未来50强：演进格局中的发展动能

November 2025 To create this report we’ve brought together PwC’s lifesciences industry experts across Deals, Audit, Consulting,Risk, and Tax. Our global network of experts in pharmaceutical,biotech, medtech and healthcare works with you to defineand deliver effective solutions so you can solve the complexchallenges facing your business, from innovation to regulationand patient engagement. Above all we aim to help you succeed, today and tomorrow.So we’ll help you shape the business strategies your futuredemands and implement the time-critical programmes andprocedures essential for success today. Our multi-disciplinaryteams and global reach enable us to offer exactly the supportyou need, wherever you need it, regardless of yourorganisation’s size. Table of contents 01Foreword05 04Methodology26 Perspectives from interviews with large corporates75Key strengths for the UK to build on—corporate perspectives75Drivers of direct investment into the UK77 06Call to action81 Endnotes 82 Contacts91 About You should not act upon the information containedin this publication without obtaining specificprofessional advice. No representation or warranty(express or implied) is given as to the accuracy orcompleteness of the information contained in thispublication, and, to the extent permitted by law,PricewaterhouseCoopers LLP, its members, employeesand agents do not accept or assume any liability,responsibility or duty of care for any consequencesof you or anyone else acting, or refraining to act,in reliance on the information contained in thispublication or for any decision based on it. PwC’s UK Life Sciences Future50 includesa selection of companies that illustrate the breadthand depth of world-class science and innovationby life sciences businesses in the UK but is neitherexclusive nor exhaustive. Company information hasbeen derived from publicly available sources.PwC has not independently verified any of thecompany information. Where statistics or researchhas been discussed in relation to any of the companiesmentioned, these have been sourced from companywebsites or information in the public domain. This publication has been prepared for generalguidance on matters of interest only and does notconstitute professional or investment advice. 01 Foreword In the two years since we compiled our first report,the volatile geopolitical and economic environmentwe highlighted then continues to create uncertainty.So, it’s testament to the resilience of the Future50companies that we find them maintaining theinnovation drive and commitment to excellence thatcharacterise the life sciences industry in the UK. When we published UK Life Sciences Future50 reportStephen AhernePharmaceutical and LifeSciences Leader, PwC UK One of our key aims in 2023 was to shine a light onthe high quality science and companies, that withthe right support and enablers, could turn the UK’sunquestionably world-leading academic research into alife sciences global powerhouse. In this report, we takea look at some of the policies and support that effect areal change. We’ve set out to explore crucial questionsregarding critical factors that will shape a world-leadingUK life sciences sector and the steps required to convertthe ambitious goals of the UK government’s Invest 2035industrial strategy into action and positive results. in October 2023, we set out to celebrate and showcasesome of the most innovative and groundbreakingcompanies operating in the UK’s life sciences sector.The Future50 were all developing exciting research inareas such as biopharmaceuticals, artificial intelligence,digital health, diagnostics and devices. In this follow up publication, Momentum in anevolving landscape, we’ve revisited the same 50companies to mark the progress they’ve made, andto explore their views of the overall context in whichthey continue to pursue their pioneering, innovativework. This update provides an opportunity to reflecton the sector’s development, acknowledge thechallenges encountered, and consider opportunitieson the road ahead. This updated report is the result of extensive interviewsand research across the UK life sciences ecosystem.We’re immensely grateful for the time and effort thatso many contributors have once again invested inhelping us to produce this report. A massive thanksto the Future50 companies and their managementteams, and to the many other market participantswho generously provided their insight and support inthe creation of this report. We remain convinced thatwith these Future50 companies and the many moregrowing in the UK, that we have a Life Sciences sectorto be immensely proud of. We hope that by addressingthe challenges head on with positive actions,the fortunes of our UK Life Sciences ecosystemand beyond can deliver on the promise, which willultimately lead to a healthier population. We’ve sought to understand what matters most tostakeholders on the ground—both to our originalFuture50 cohort and to large life sciences c